BaFin Identifies Errors in Dermapharm's 2025 Consolidated Financial Statements
11/20/2026
Impact: -65
Unknown
BaFin concluded that Dermapharm Holding SE’s 2025 consolidated financial statements were erroneous, citing two accounting violations. The company failed to record at least €1.9 million in impairment on a €63.2 million receivable, overstating other long-term assets under IFRS 9. It also failed to disclose that business volume with its parent company rose from €7.0 million to €70.8 million, primarily because of a €70.0 million loan, contrary to IAS 24.
AI summary, not financial advice
Share: